Fenbendazole-d3

Fenbendazole-d3 is a deuterium labeled Fenbendazole. Fenbendazole-d3 is a HIF-1α agonist and activates the HIF-1α-related GLUT1 pathway. Fenbendazole is an orally active benzimidazole anthelmintic agent, with a broad antiparasitic range. Fenbendazole is a microtubule destabilizing agent. Fenbendazole causes cell-cycle arrest and mitotic cell death, and has antitumor activity in mice xenografted with wild-type p53[1][2][3][4].

Product Specifications

CAS Number

[1228182-47-5]

UNSPSC

12352005

Hazard Statement

H361, H373, H410

Target

Antibiotic; HIF/HIF Prolyl-Hydroxylase; Microtubule/Tubulin; Parasite

Type

Isotope-Labeled Compounds

Related Pathways

Anti-infection; Cell Cycle/DNA Damage; Cytoskeleton; Metabolic Enzyme/Protease

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Infection

Purity

99.70

Solubility

DMSO : 5mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(OC([2H])([2H])[2H])NC1=NC2=CC=C(SC3=CC=CC=C3)C=C2N1

Molecular Formula

C15H10D3N3O2S

Molecular Weight

302.37

Precautions

H361, H373, H410

References & Citations

[1]Nilambra Dogra, et al. Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Sci Rep. 2018 Aug 9;8 (1) :11926.|[2]Hossein Aleyasin, et al. Antihelminthic benzimidazoles are novel HIF activators that prevent oxidative neuronal death via binding to tubulin. Antioxid Redox Signal. 2015 Jan 10;22 (2) :121-34.|[3]Qiwen Duan, et al. Fenbendazole as a potential anticancer drug. Anticancer Res. 2013 Feb;33 (2) :355-62.|[4]Jia Xu, et al. miR-143-5p suppresses breast cancer progression by targeting the HIF-1α-related GLUT1 pathway. Oncol Lett. 2022 May;23 (5) :147.